Furosemide Fails to Reduce Risk of Dangerous de novo Postpartum Hypertension: New Research
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.
Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial
Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.
Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study
The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.
2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine
The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.
Alzheimer Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET
Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.
Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD
Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.
Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data
In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis
Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.
Dupilumab, Ensifentrine Added to 2025 GOLD Guidelines for COPD: Expert Parses Recommendations
Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.
Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD
Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.
FDA Approves Monthly IV Maintenance Dosing of Lecanemab for Adults with Early Alzheimer Dementia: A First in Long-Term Disease Management
Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.
3 Studies on Major Depressive Disorder: Physical, Pharmacologic, and Neuromodulatory Interventions Explored
Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.
Environment is a Primary Nonpharmacologic Intervention to Reduce Agitation in Alzheimer Disease, Geriatric Psychiatrist Explains
When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.
Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains
The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.
2025 GOLD Report on COPD Addresses Cardiovascular Risk in New Section: MeiLan Han, MD, MS, Highlights Rationale
Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.
Vaccine Hesitancy in the Chronic Conditions Community: New Survey Findings
People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.
Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis
There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.
Two Plasma Proteins May Serve as Early Biomarkers for Alzheimer Dementia and Help Explain Sex Differences, Study Suggests
Levels of acetyl-L-carnitine and free carnitine correlated significantly with disease severity, particularly in women with moderate and severe Alzheimer dementia.
"Be Vigilant About Risk Factors for COPD, Aggressive with Questions About Symptoms," Expert Advises Primary Care
COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.
Most People Who Monitor Health with Wearable Devices Don't Share Data with Clinicians
Only 25% of people who self-monitor health use the data to inform their physicians.
Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers
The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.
Expert Perspectives 2024: Biologics for Management of COPD with MeiLan K Han, MD, MS
The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.
Attitudes Toward Vaccines in the Chronic Conditions Community: Survey Highlights
Hesitancy about vaccination against dangerous communicable diseases remains a public health problem, particularly when the hesitant are living with immunocompromising conditions.
Obesity and Venous Disease: An Expert Discussion
Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.
GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored
Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.
Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity
The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.
Tralokinumab Dosing Every 4 Weeks is Effective Maintenance Regimen for Atopic Dermatitis, Study Suggests
The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.
RSVPreF Reduces Risk of Severe RSV in Older, High-Risk Adults in Large Real-World Study
The new research augments data on efficacy of RSVPreF in older, high-risk adults that was not captured in phase 3 pivotal clinical trials, authors said.
Zyn Nicotine Pouches Get FDA Nod But Not Without Warnings
Agency review determined the pouches to be less harmful to health than cigarettes and an aid to smoking cessation but did not declare the products "safe."
